Liver Transplant; Complications Clinical Trial
Official title:
Determine the Safety/Efficacy of Ticagrelor in Post-transplant Patients With Hepatic Artery Thrombosis (HAT)
Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after Pediatric liver transplantation. Ticagrelor (a new reversible inhibitor of P2Y12 receptor with faster onset of action and greater platelet inhibition) was used to treat patients with pediatric post-transplant hepatic artery thrombosis (HAT) compared to low molecular weight heparin.
In pediatric patients with post-transplant hepatic artery thrombosis (HAT) , low molecular weight heparin is a commonly used method. Ticagrelor, a direct-acting and reversible ADP receptor antagonist, is now the most commonly used ADP receptor antagonist in the treatment of coronary diseases. Compared to its predecessor clopidogrel, the pharmacokinetic profil of ticagrelor is more predictable, demonstrating a faster onset of action and a more consistent platelet inhibition. However, because of the excellent antithrombotic effect and increased bleeding potential, it is recommended that major bleeding, such as OPCAB or CABG surgery, be expected with a high probability, and in case of fatal surgery, the drug should be discontinued for 5 days. The present study is to evaluate the safety and efficacy of Ticagrelor in pediatirc receipt with post-operative HAT. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05818644 -
Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
|
||
Not yet recruiting |
NCT06041490 -
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
|
Phase 2 | |
Recruiting |
NCT04443322 -
Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
|
N/A | |
Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
Completed |
NCT03165916 -
Study to Compare the Incidence of Biliary Complications After Liver Transplantation
|
N/A | |
Withdrawn |
NCT04216303 -
Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus
|
||
Recruiting |
NCT04506398 -
Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
|
||
Not yet recruiting |
NCT05853484 -
Home-based Bimodal Lifestyle Intervention in Patients With Liver Cirrhosis Awaiting Orthotopic Liver Transplantation
|
N/A | |
Not yet recruiting |
NCT05036031 -
Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
|
||
Recruiting |
NCT05065125 -
Clinical Usefulness of Digital Single-operator Cholangioscopy(SpyGlass™) for Post-liver Transplant Anastomotic Stricture
|
||
Recruiting |
NCT06060392 -
Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
|
N/A | |
Enrolling by invitation |
NCT05195944 -
Semaglutide vs Sitagliptin
|
Phase 4 | |
Completed |
NCT05255510 -
Risk of Acute Kidney Injury in Living Liver Donor Surgery
|
||
Not yet recruiting |
NCT06048445 -
Placement of Biliary Drainage Stent to Prevent Biliary Intestinal Anastomosis After Liver Transplantation in Children
|
||
Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
Completed |
NCT04182256 -
Magnetic Spiderman for Preparation of Liver Donation
|
N/A | |
Recruiting |
NCT04327427 -
Outcome Analysis of Aspirin in Liver Transplantation
|
||
Recruiting |
NCT04477967 -
Design and Implementation of the Pediatric Liver Transplantation Biobank
|
||
Recruiting |
NCT05109156 -
Preoperative Sepsis Timeline, Profile and Its Association With Recipient Outcome Following Live Donor Liver Transplant
|
||
Recruiting |
NCT06124209 -
Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial
|
Phase 4 |